121 results about "Bovine respiratory disease" patented technology

The present invention 10 provides a system and method of monitoring and tracking a plurality of physical variables from a remote location. The invention 10 utilizes a plurality of radio frequency identification transponders 20 each coupled with a sensor for measuring physical data. The transponders 20 are powered by a radio frequency reader / interrogator 60 that provides radio frequency excitation to the transponders 20 and receives and demodulates back-scattered signals therefrom. The invention 10 is particularly advantageous in monitoring temperature in cattle herds as an aid to early diagnosis of bovine respiratory disease.

A method for altering the electromagnetic environment of respiratory tissues, cells, and molecules comprising establishing baseline thermal fluctuations in voltage and electrical impedance at a respiratory target pathway structure depending on a state of the respiratory tissue, configuring at least one waveform to have sufficient signal to noise ratio to modulate at least one of ion and ligand interactions whereby the at least one of ion and ligand interactions are detectable in the respiratory target pathway structure above the established baseline thermal fluctuations in voltage and electrical impedance, generating an electromagnetic signal from the configured at least one waveform; and coupling the electromagnetic signal to the respiratory target pathway structure using a coupling device.

Therapeutically effective anti-viral compositions, useful especially against respiratory diseases caused or mediated by respiratory syncytial virus (RSV) are disclosed, wherein said compositions comprise at least one anti-RSV antibody, including high affinity antibodies, and an additional anti-inflammatory agent, especially corticosteroids, as well as anti-inflammatory antibodies, especially anti-interleukin-6. Also disclosed are methods of using such compositions to treat and / or prevent respiratory diseases. Such compositions may optionally contain other non-antibody anti-viral agents.

In the case of disease in the respiratory organs of creatures, which especially inhabit in terms of overcrowding, the danger of spreading a disease throughout the entire breeding farm is perfectly evident. The use of traditional methods, such as the stethoscope, for examining the respiratory organs of each creature, in the mode of their direct contact listening, is impossible in most due to the specific spatial arrangement of creatures in breeding farms and / or infectious danger to a veterinary. Moreover, the acoustic signs of the said illness at its early stage cannot be heard audibly with use of traditional methods. The present invention provides a novel method of ultrasound non-contact early detection of respiratory diseases in fowl and mammals, and other breathing creatures of animate nature, wherein innovative technology is applied for revealing the suspected minimal unit group with sick creature(s); wherein the said technology includes at least the following interrelated techniques: I-Stationary 3-D Surveying Technique that enables to identify vectored direction(s) to suspected sections in total creatures' inhabiting area by electronically scanning the said total area with 3-D array of ultrasonic transducers. II-Portable 2-D Inspection Technique that permits to verify disposition of perfect suspected sectional area by locating around each suspected inhabiting section with portable and hand-held ultrasonic detecting devices. III-Local 1-D Pinpointing Technique that provides for pinpointing a distinct suspected unit group, being inside an infected inhabiting sector, by a hand-held ultrasound pick-up device, equipped with extending acoustic probes for veterinary safety. Portable and Local Techniques optionally provides for use of wireless processing with Data Processing System. Spatio-Temporal compliance in applying the said techniques is being considered by operational algorithm of Data Processing System.

A method of influencing bronchoconstriction in a mammal comprising applying a stimulation in one or more regions of the brain of the mammal, and an apparatus therefore. The method and apparatus may be used to treat a respiratory disease or sleep apnea.

A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., Pd(II)-, Ni(II)-, or Fe(II)-ligand of Formula (A)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers Y. The provided supramolecular complexes are able to form gels (e.g., hydrogels). The gels are suprametallogels and exhibited excellent mechanical properties without sacrificing self-healing and showed high robustness and storage modulus. The present disclosure further provides compositions (e.g., gels) that include the nanostructures or supramolecular complexes and optionally an agent (e.g., small molecule), where the nanostructures and the nanostructure moieties of the supramolecular complexes may encapsulate and slowly release the agent. The nanostructures, supramolecular complex, and compositions may be useful in delivering an agent to a subject, tissue, or cell, as super-absorbent materials, and in treating a disease (e.g., a genetic diseases, proliferative disease (e.g., cancer or benign neoplasm), hematological disease, neurological disease, gastrointestinal disease (e.g., liver disease), spleen disease, respiratory disease (e.g., lung disease), painful condition, genitourinary disease, musculoskeletal condition, infectious disease, inflammatory disease, autoimmune disease, psychiatric disorder, or metabolic disorder).

The invention discloses a GeXP (Gene Expression) rapid detection kit capable of simultaneously identifying six virus of chicken respiratory disease. The GeXP rapid detection kit is used basing on a CeXP system and contains seven PCR (Polymerase Chain Reaction) primer pairs, the specificity for simultaneously detecting avian influence virus, H5, H7 and H9 sub type of the avian influence virus, Newcastle disease virus, infectious bronchitis virus and infectious laryngotracheitis virus is strong, the sensitivity can be up to 100 copy / mu l, and compared with an identifying result of regular test methods such as virus isolation and hemagglutination inhibition, the coincidence rate is up to 100%. According to the GeXP rapid detection kit disclosed by the invention, a simple and high-throughput detection kit and a detection system are provided for the detection of common main chicken viral respiratory disease, the actual needs are accordant, and the application prospect is wide.

The present invention discloses an application of pentacyclic triterpenoid saponin represented by formulas (I) to (XIII) for the preparation of a medicine for preventing or treating AMPK-mediated diseases including fatty liver disease, inflammatory bowel disease, respiratory disease, diabetic complications and polycystic kidney disease. The compounds of formula (I) to (XIII) are especially usefulfor nonalcoholic simple fatty liver, nonalcoholic steatohepatitis, non-alcoholic steatohepatitis-induced cirrhosis, ulcerative colitis, Crohn's disease, chronic obstructive Pulmonary diseases, asthma,idiopathic pulmonary fibrosis, cystic fibrosis, allergic rhinitis, diabetic nephropathy, diabetic cardiomyopathy, diabetic ulcers, and autosomal dominant polycystic kidney disease. A pharmaceutical composition for preventing and treating the AMPK-mediated diseases of the present invention comprises a therapeutically effective amount of the compounds of the formula (I) to (XIII) or a pharmaceutically acceptable salt or a solvate thereof as an active ingredient and a pharmaceutically acceptable excipient.

Compounds of Formula (1.0.0):are described wherein A is for example aryl, heteroaryl or heterocyclyl, Y is preferably -C(=O)-; B is independently selected from a group of moieties, the most preferred of which are those of partial Formulas (1.1.2) and (1.1.6):and E is a single bond; oxygen; 1,1-cyclopropyl; C(CH3)2; CF2; or a bridging moiety of partial Formula (1.9.0):where R1a is hydrogen when R1 has the meaning of a mono-valent substituent; and R1a is a single bond when R1 has the meaning of a di-valent substituent. Said compounds are useful in methods of treating or preventing an inflammatory, autoimmune or respiratory diseases by inhibiting cell adhesion and consequent or associated pathogenic processes subsequently mediated by VLA-4.

The present invention provides a method of measuring an acoustic impedance of a respiratory system. The method comprises selecting a frequency range for an acoustic wave, directing the acoustic wave into the respiratory system and receiving an acoustic wave from the respiratory system. The method also comprises determining the acoustic impedance for a plurality of volumes or volume ranges of the respiratory system. Each volume, or the volumes within each volume range, is larger than RV or FRC and smaller than TLC whereby the determined acoustic impedances are specific for respective volumes or volume ranges. Further, the method includes determining a volume, or volume range, dependency of the acoustic impedance of the respiratory system and charaterising the respiratory system by analysing the dependency of the acoustic impedance on the volume or volume range.

Novel formulations containing a fluorinated chloramphenicol or thiamphenicol derivative antibiotic such as florfenicol, and methods for using such formulations in the treatment and prevention of infectious diseases of bovines and swine, including bovine respiratory disease.

A method of treating a human subject which is effected by intermittent breathing cycle-coordinated pulse delivery inhalation of gaseous nitric oxide at a concentration of at least 160 ppm, or at a load per cycle of 80 ppm-hour, is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

A system and method are provided for diagnosis of bovine respiratory diseases using auscultation techniques wherein the acoustic characteristics of a recorded spectrogram is compared with existing data enabling a caregiver to make a diagnosis for a diseased animal. Lung sounds are obtained by use of an electronic stethoscope, and the sounds are stored as digital data. Signal conditioning is used to place the data in a desired format and to remove undesirable noise associated with the recorded sounds. An algorithm is applied to data, and lung scores are calculated. The lung scores are then categorized into various levels of perceived pathology / disease within the animal based upon baseline data that categorizes the lung scores. From the lung scores, a caregiver may then associate a diagnosis, prognosis, and a recommended treatment. Analysis software in the present invention generates the lung scores from the recorded sounds, and may also provide the user a visual display of presumptive diagnoses as well as recommended treatments.

The present invention relates to a kit for simultaneous diagnosis of viral respiratory diseases. To be more specific, the present invention is directed to a method for diagnosing viral respiratory diseases by detecting the genes specific to the respiratory disease-causing virus, a primer set for diagnosing the viral respiratory diseases used in the diagnosis method, a composition for simultaneous diagnosis of viral respiratory diseases, comprising the primer set, and a kit for simultaneous diagnosis of viral respiratory diseases, comprising the composition. When the primer set of the present invention for diagnosing the viral respiratory diseases is used, 14 different types of respiratory viruses can be simultaneously detected only with one reaction through real-time multiplex reverse transcription (RT)-PCR, and the onset of respiratory diseases caused by these viruses can be diagnosed. Thus, the primer set of the present invention can be widely used for prompt diagnosis and treatment of respiratory diseases.

The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., Pd(II)-, Ni(II)-, or Fe(II)-ligand of Formula (A)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers Y. The provided supramolecular complexes are able to form gels (e.g., hydrogels). The gels are suprametallogels and exhibited excellent mechanical properties without sacrificing self-healing and showed high robustness and storage modulus. The present disclosure further provides compositions (e.g., gels) that include the nanostructures or supramolecular complexes and optionally an agent (e.g., small molecule), where the nanostructures and the nanostructure moieties of the supramolecular complexes may encapsulate and slowly release the agent. The nanostructures, supramolecular complex, and compositions may be useful in delivering an agent to a subject, tissue, or cell, as super-absorbent materials, and in treating a disease (e.g., a genetic diseases, proliferative disease (e.g., cancer or benign neoplasm), hematological disease, neurological disease, gastrointestinal disease (e.g., liver disease), spleen disease, respiratory disease (e.g., lung disease), painful condition, genitourinary disease, musculoskeletal condition, infectious disease, inflammatory disease, autoimmune disease, psychiatric disorder, or metabolic disorder).

The invention discloses a pig house capable of monitoring respiratory diseases. The pig house comprises a roof, wall bodies, and enclosures for breeding live pigs, and also comprises a ventilation system, a disinfection system and a respiratory disease monitoring system, wherein the respiratory disease monitoring system comprises a reminding device, collecting devices worn on the live pigs and information processing devices arranged on the enclosures, wherein each collecting device comprises a voice collecting module and an electricity generating module, and each of the information processing devices comprises a voice preprocessing module, a feature extracting module and a cough recognition module. The technical scheme effectively reduces the data volume for processing and increases the recognition rate so as to effectively decrease the risk that the live pigs are infected with the respiratory diseases in the pig house.

A pharmaceutical composition comprising: (a) a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; R2 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; and R3 is hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH, or O—C1-4-alkylene-COO—C1-4-alkyl, or an enantiomer, mixture of enantiomers, or racemate thereof, or an acid addition salt with pharmacologically acceptable acids thereof, or a solvate or hydrate thereof; and (b) another active substance 2, wherein the molar ratio of the compound of formula 1 to the active substance 2 is 1:10 to 12:1.

Novel transdermal preparations combining a non-steroidal anti-inflammatory drug (NSAID) such as flunixin, are disclosed. Methods for using and administering such preparation in the treatment of inflammatory conditions in bovines, including bovine respiratory disease, are also disclosed.

Compounds of Formula (1.0.0):are described wherein A is for example aryl, heteroaryl or heterocyclyl, Y is preferably -C(=O)-; B is independently selected from a group of moieties, the most preferred of which are those of partial Formulas (1.1.2) and (1.1.6):and E is a single bond; oxygen; 1,1-cyclopropyl; C(CH3)2; CF2; or a bridging moiety of partial Formula (1.9.0):where R1a is hydrogen when R1 has the meaning of a mono-valent substituent; and R1a is a single bond when R1 has the meaning of a di-valent substituent. Said compounds are useful in methods of treating or preventing an inflammatory, autoimmune or respiratory diseases by inhibiting cell adhesion and consequent or associated pathogenic processes subsequently mediated by VLA-4.

The invention discloses compound florfenicol injection and a preparation method and application thereof. The compound florfenicol injection comprises main medicaments, injection solvent and local anodyne; and the main medicaments are florfenicol and flunixin meglumine. The compound florfenicol injection is safe and convenient to use, controllable in quality, stable in preparation process, suitable for industrialized production and low in cost; and the compound florfenicol enhances the prevention and treatment effects of porcine or bovine respiratory diseases, improves the survival rate of pigs or cattle, and is suitable for popularization and application.

The invention provides an intelligent assisted diagnosis method for children respiratory diseases and a diagnosis system thereof. The method comprises the steps of S1, acquiring assisted examination information of a to-be-diagnosed child and / or doctor interrogation diagnosis recording information; S2, according to the assisted examination information and / or doctor interrogation diagnosis recordinginformation, screening key information; and S3, according to a pre-established children disease knowledge database system, processing the key information by means of a pre-trained typical symptom diagnosis model, thereby obtaining a diagnosis result. The diagnosis result comprises at least one possible disease, and the characteristic, which corresponds with each possible disease, of the to-be-diagnosed child. The intelligent assisted diagnosis method can help non-expert doctors in improving diagnosis levels for difficult disease, thereby reducing misdiagnosis.

The invention discloses a colloidal gold method detection test strip and a reagent kit for an IgG antibody of a respiratory disease and a preparation method of the reagent kit. The test strip determines the IgG antibody by using a principle of an immunocapture method; respiratory herpes viruses, adenoviruses, influenzaviruses and an IgG antibody of mycoplasma pneumoniae can be detected jointly by one operation; the operation process is simplified; the test strip is simple, convenient, rapid and accurate in detection, suitable for mass detection and applicable to primary screening and epidemiological survey; and a result is distinct and easy to distinguish.

Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g., inhaler, intranasal delivery device) for the treatment or prevention of lung inflammation or a respiratory disease, and a delivery device for the treatment or prevention of lung inflammation or a respiratory disease that contains an agent as described herein.

The invention relates to a compound oral medicine composition for treating respiratory disease of animals, in particular to a compound oral medicine composition for treating the respiratory disease of pigs and cattle. The composition contains tulathromycin with effective quantity and nonsteroidal antipyretic and analgesic.

There is provided, a method of diagnosing a disease state in a subject comprising: (a) obtaining nuclear magnetic resonance data on an obtained biological sample from the subject; (b) performing a statistical analysis on the nuclear magnetic resonance data; (c) determining a subject profile for the biological sample based on the statistical analysis; (d) comparing the subject profile to a predetermined profile for differentiating between: (i) the disease state and a non-diseased state; (ii) a first disease state and a second disease state, or (iii) the first disease state, the second disease state, and the non-diseased state, to provide a diagnosis of the disease state, wherein the comparing does not comprise identification of components of the biological sample.

Described herein are compounds and compositions, and methods for using the compounds and compositions, for treating respiratory diseases and illness, such as severe acute respiratory syndrome (SARS).